Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development.
In a bid to increase access to mRNA vaccines to protect against a range of diseases in Africa, the Bill & Melinda Gates Foundation has pledged to give USD $40m to biotechs and vaccine manufacturers around the world, including a Belgian biotech company and two leading African vaccine manufacturers
Quantoom Biosciences, based in Nivelles, Belgium, will receive USD $20m. Additionally, the Institut Pasteur de Dakar based in Senegal and Biovac based in South Africa will each receive USD $5m for the purchase of new technologies. USD $10m will be made available to other vaccine manufacturers keen to use the platform.
Vaccine accessibility and inequality was highlighted throughout the COVID-19 pandemic, with low-income countries disproportionately affected. These countries are oftentimes also the most affected by diseases such as malaria and tuberculosis that can be prevented with proper vaccination. Various initiatives, such as the WHO’s mRNA vaccine technology hub in Cape Town that opened in April 2023, have sought to address this issue of vaccine inequity. With the aid of this initiative, Afrigen Biologics became the first manufacturers to produce Africa’s first-ever mRNA vaccine against COVID-19. However, the scale of vaccine production and launch remain an expensive endeavour.
Quantoom hopes to utilise its Ntensify platform to allow vaccine manufacturers to batch-produce mRNA vaccines more efficiently and inexpensively. Chief Executive of the Institut Pasteur de Dakar Dr Amadou Sall states “[This] is an important and necessary step towards vaccine self-reliance in the region.” Afrigen has already started using the Ntensify platform in the development of vaccines for Rift Valley fever and gonorrhoea. Compared to traditional mRNA development technology, the Gates Institute and Afrigen have claimed that they can cut development costs by half. Petro Terblanche, Afrigen’s Chief Executive comments that “The second generation of mRNA is to reduce the cost.”
Source: Gates gives $40 mln to boost access to mRNA vaccines in Africa [Accessed 16 October 2023] Gates gives $40 mln to boost access to mRNA vaccines in Africa | Reuters
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...